About Epigeneres
Epigeneres is a Healthcare company based in Mumbai (India) founded in 2008. It operates as a genomics-based cancer diagnostic tests are offered by Epigeneres. Epigeneres has raised $9.83 million across 3 funding rounds from investors including HCG, Kotak Mahindra Bank and Torrent Pharma. The company has 76 employees. Epigeneres was last valued at $121.84 million in December 2021. Its Indian entity Epigeneres Biotech Private Limited reported revenue of ₹7.42 Cr. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Pan Cancer. Its competitors include GRAIL, Color, Earli, Biovica and RainDance and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
Provider of genomics based diagnostic tests for cancer. It offers HrC Test a proprietary blood-based diagnostic capable of detecting all types of cancers, including solid tumors, hematological malignancies, and soft tissue sarcomas and B (Blood-Based Biopsy) test for genetic analysis that provides deep insights into cancers presence, progression, and treatment pathways. It also offer Nutrigenomic Products such as NovaGenere and nCurcu which feature plant-based phytoextracts, antioxidants that are targeted at cellular rejuvenation, antiinflammation, and healthy aging.
- Headquarters Mumbai, India
- Employees 76
- Stage Minicorn
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website epigeneres.com
- Social LinkedIn X Facebook
- Legal Name Epigeneres Biotech Private Limited
- Date of Incorporation 25 Apr, 2012
- Jurisdiction Mumbai, Maharashtra, India
- Annual Revenue₹7.42 Cr
FY 2025 · +185% YoY
- Net Loss-₹17.26 Cr
FY 2025 · -233% margin
- EBITDA-₹6.71 Cr
FY 2025 · -90% margin
- Total Equity Funding$9.83M (USD)
in 3 rounds
- Latest Funding Round$1.98M (USD), Series B
Jun 2024
- InvestorsHCG
& 38 more
- Employee Count76
Associated legal entities of Epigeneres
Epigeneres operates through Epigeneres Biotech Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Epigeneres Biotech Private Limited CIN U29253MH2012PTC230235 | Active | 25 Apr 2012 | Mumbai, Maharashtra | ₹7.4 Cr | 76 | 7 | View details |
Funding Insights of Epigeneres
Epigeneres has successfully raised a total of $9.83M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $1.98 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $9.83M
- Total Rounds 3
- Last Round Series B — $1.98M
- First Round $1.85M
(Apr 2018)
- Investors Count 39
All 3 funding rounds of Epigeneres with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2024 | $1.98M | Series B | – | Finessefabricrentals, Yash Bajpai | |
| Dec 2021 | $6M | Series B | $121.84M | Moez Daya, LetsVenture | |
| Apr 2018 | $1.85M | Series A | $43.82M | Torrent Pharma |
| Date | Valuation | Stage |
|---|---|---|
| Dec 2021 | $121.84M | •••••••• |
| Apr 2018 | $43.82M | •••••••• |
Last known valuation $121.84M (Dec 2021). 39 investors in total: 24 institutional and 15 angel.
Investors in Epigeneres
Epigeneres has secured backing from 39 investors, including angel, institutional, and venture fund investors. Prominent investors backing the company include HCG, Kotak Mahindra Bank and Torrent Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Angel investment firm providing investment solutions | – | shripadamventures.tcc.mode | Bengaluru, India | |
Venture capital firm focused on early-stage investments | – | vmspice.tcc.mode | Guntur, India | |
Seed-stage venture capital investments are targeted by Singhvi Heritage. | – | sanghviherirtage.tcc.mode | Chennai, India | |
Multiple sectors are invested in by the private equity firm. | – | sjtconstructions.tcc.mode | Andheri, India | |
Online platform that connects startup founders with accredited investors, enabling early-stage fundraising and investment opportunities for private market growth | 2013 | letsventure.com | Bengaluru, India | |
Advisory services are provided by East River Advisors LLC. | – | eastriveradvisorsllc.com | - | |
- | – | nanditaadvisors.tcc.mode | - | |
Provider of investment advisory services | – | kotakinvestmentadvisors.tcc.mode | Mumbai, India | |
Commercial banking services are offered to corporate and retail customers. | 1985 | kotak.com | Mumbai, India | |
- | – | thescottfamilytrust.tcc.mode | - |
Investor details for Epigeneres
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Epigeneres Biotech Private Limited (Epigeneres)
Epigeneres Biotech Private Limited is the primary company behind Epigeneres. The board of Epigeneres Biotech Private Limited currently have 7 directors; the longest-serving is Krishnan Venkata Challam, appointed in 2016. 8 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Krishnan Venkata Challam DIN 00034473 | Director | 29 Feb 2016 | 10 yrs 7 mo | Epigeneres Biotech Private Limited |
| Ashish Vinaykumar Tripathi DIN 06941116 | Director | 29 Feb 2016 | 10 yrs 7 mo | Epigeneres Biotech Private Limited |
| Anish Tripathi DIN 03383586 | Managing Director | 05 May 2019 | 7 yrs 5 mo | Epigeneres Biotech Private Limited |
| Amish Tripathi DIN 06932791 | Director | 21 Jun 2021 | 5 yrs 3 mo | Epigeneres Biotech Private Limited |
| Bhavna Roy DIN 03214372 | Director | 10 Jan 2022 | 4 yrs 9 mo | Epigeneres Biotech Private Limited |
| Moez Rajabali Rahemtulla Daya DIN 09431890 | Nominee Director | 10 Jan 2022 | 4 yrs 9 mo | Epigeneres Biotech Private Limited |
| Sanjay Pravinchandra DIN 03033677 | Director | 30 Sep 2023 | 3 yrs | Epigeneres Biotech Private Limited |
People of Epigeneres
1 people are tracked at Epigeneres (1 in leadership); the tracked headcount is 76.
| Name | Role | Group |
|---|---|---|
| Managing Director | Leadership |
Complete people profiles for Epigeneres
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Epigeneres
Figures of Epigeneres Biotech Private Limited, the primary company behind Epigeneres, for FY 2025. Revenue was ₹7.42 Cr (+185% year on year). Net loss was -₹17.26 Cr (-233% margin). EBITDA was -₹6.71 Cr (-90% margin). Revenue has grown at a compounded annual rate of +57% over three years and +59% over five years.
- ₹7.42 CrRevenue · FY 2025 · +185% YoY
- -₹17.26 CrNet loss · -233% margin
- -₹6.71 CrEBITDA · -90% margin
- ₹2.6 LakhPaid-up capital
- 76Employees (provident fund records)
- +57%Revenue CAGR, 3 years
- +59%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Epigeneres Biotech Private Limited are on its company page.
Detailed financial statements for Epigeneres
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Epigeneres
4 dated milestones of Epigeneres across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Epigeneres is founded.
- Funding First funding round of $1.8M.
- Milestone Reaches Minicorn status.
- Funding Latest funding round, Series B, of $2.0M.
Competitors of Epigeneres
Epigeneres has 9 listed competitors in our database, 8 of them funded. They include GRAIL, Color, Earli, Biovica and RainDance, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| grail.com | 2016 | Menlo Park, United States | $2B | 491 | Circulating tumor DNA is screened for early cancer detection. | |
| color.com | 2013 | Burlingame, United States | $491.44M | 687 | Cancer care is delivered through a virtual clinic by Color. | |
| earli.com | 2018 | San Francisco, United States | $40M | 38 | Early cancer detection tests are developed using synthetic biomarkers. | |
| biovica.com | 2009 | Uppsala, Sweden | $4.27M | 13 | Tumor response to cancer therapies is monitored via specialized assays. | |
| raindancetech.com | 2004 | Billerica, United States | $111.66M | 105 | Developer of nucleic acid detection and quantification systems | |
| volition.com | 1995 | Gembloux, Belgium | – | – | Volition is focused on developing epigenetic diagnostic solutions. | |
| predicine.com | 2015 | Hayward, United States | $41.31M | 23 | Developer of liquid biopsy assays and biomarker discovery for cancer | |
| accuragen.com | 2013 | Menlo Park, United States | $46.9M | – | Non-invasive cancer diagnostics tests are developed using ssDNA sequencing technology. | |
| novellusdx.com | 2011 | Jerusalem, Israel | $85.5M | – | Developer of technology for precision cancer diagnosis and therapies |
Detailed competitors of Epigeneres
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Epigeneres
The website of Epigeneres (epigeneres.com) receives about 1.7K visits a month.
- Monthly visits1.7K
▲ 8.8% vs previous month
Websites whose visitors overlap most with Epigeneres. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biogenomics.co.in | 100% | – | – | View details | |
| bombayhospital.com | 94% | 34.3K | #690,031 | View details |
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as Epigeneres (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Epigeneres
Complete news archive for Epigeneres
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Epigeneres
Epigeneres was founded in 2008 and raised its 1st funding round 10 years after it was founded.
Epigeneres is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Epigeneres is a funded company, having raised a total of $9.83M across 3 funding rounds to date. The company's 1st funding round was a Series A of $1.85M, raised on Apr 2018.
Epigeneres has 76 employees.
The primary company behind Epigeneres, Epigeneres Biotech Private Limited, reported revenue of ₹7.42 Cr for FY 2025, up 185% year on year.
Provider of genomics based diagnostic tests for cancer. It offers HrC Test a proprietary blood-based diagnostic capable of detecting all types of cancers, including solid tumors, hematological malignancies, and soft tissue sarcomas and B (Blood-Based Biopsy) test for genetic analysis that provides deep insights into cancers presence, progression, and treatment pathways. It also offer Nutrigenomic Products such as NovaGenere and nCurcu which feature plant-based phytoextracts, antioxidants that are targeted at cellular rejuvenation, antiinflammation, and healthy aging.
Epigeneres has 39 investors. Key investors include HCG, Kotak Mahindra Bank, Torrent Pharma, LetsVenture, and Silversky Builders.
The valuation of Epigeneres is $121.84M as of Dec 2021.
Epigeneres operates through Epigeneres Biotech Private Limited.
The legal entities of Epigeneres currently have 7 directors, including Bhavna Roy, Krishnan Venkata Challam, Anish Tripathi and others.